Dominika Bhatia

Dominika Bhatia

Auto-generated profile, based on publicly available information

Dominika Bhatia

Centre for Chronic Disease and Population Health Research, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 March 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
DBDominika Bhatia
Dominika Bhatia
SMSujata Mishra
Sujata Mishra
AKAbirami Kirubarajan
Abirami Kirubarajan
BYBernice Yanful
Bernice Yanful
SASara Allin
Sara Allin
ERErica Di Ruggiero
Erica Di Ruggiero
Objectives Financial risk protection (FRP) is an indicator of the Sustainable Development Goal 3 universal health coverage (UHC) target. We sought to characterise what is known about FRP in the UHC context and to identify evidence gaps to prioritise in future research. Design Scoping overview of reviews using the Arksey & O’Malley and Levac & Colquhoun framework and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews reporting guidelines. Data sources MEDLINE, PsycINFO, CINAHL-Plus and PAIS Index were systematically searched for studies published between 1 January 1995 and 20 July 2021. Eligibility criteria Records were screened by two independent reviewers in duplicate using the following criteria: (1) literature review; (2) focus on UHC achievement through FRP; (3) English or French language; (4) published after 1995 and (5) peer-reviewed. Data extraction and synthesis Two reviewers extracted data using a standard form and descriptive content analysis was performed to synthesise findings. Results 50 studies were included. Most studies were systematic reviews focusing on low-income and middle-income countries. Study periods spanned 1990 and 2020. While FRP was recognised as a dimension of UHC, it was rarely defined as a concept. Out-of-pocket, catastrophic and impoverishing health expenditures were most commonly used to measure FRP. Pooling arrangements, expansion of insurance coverage and financial incentives were the main interventions for achieving FRP. Evidence gaps pertained to the effectiveness, cost-effectiveness and equity implications of efforts aimed at increasing FRP. Methodological gaps related to trade-offs between single-country and multicountry analyses; lack of process evaluations; inadequate mixed-methods evidence, disaggregated by relevant characteristics; lack of comparable and standardised measurement and short follow-up periods. Conclusions This scoping overview of reviews characterised what is known about FRP as a UHC dimension and found evidence gaps related to the effectiveness, cost-effectiveness and equity implications of FRP interventions. Theory-informed mixed-methods research using high-quality, longitudinal and disaggregated data is needed to address these objectives.

17 January 2023 in Humanities and Social Sciences Communications
Verified
Journal Article
Open access
PDF file
DBDominika Bhatia
Dominika Bhatia
SASara Allin
Sara Allin
ERErica Di Ruggiero
Erica Di Ruggiero
The procurement and provision of expert-driven, evidence-informed, and independent science advice is integral to timely decision-making during public health emergencies. The 2019 coronavirus disease (COVID-19) pandemic has underscored the need for sound evidence in public health policy and exposed the challenges facing government science advisory mechanisms. This paper is a jurisdictional case study describing (i) the federal science advice bodies and mechanisms for public health in Canada (i.e., the federal science advice “ecosystem”); and (ii) how these bodies and mechanisms have mobilized and evolved to procure expertise and evidence to inform decisions during the first two years of the COVID-19 pandemic. We reviewed publicly accessible Government of Canada documents, technical reports, and peer-reviewed articles available up to December 2021. Canada’s federal landscape of science advisory bodies for public health within the Health Portfolio was largely shaped by Canada’s experiences with the 2003 severe acute respiratory syndrome and 2009 H1N1 outbreaks. In parallel, Canada has a designated science advisory apparatus that has seen frequent reforms since the early 2000s, with the current Office of the Chief Science Advisor created within the Science Portfolio in 2018. The COVID-19 pandemic has further complicated Canada’s science advice ecosystem, with involvement from departments, expert advisory groups, and partnerships within both the federal Health and Science Portfolios. Although the engagement of federal departments outside the health sector is promising, the COVID-19 experience in Canada supports the need to institutionalize science advisory bodies for public health to improve pandemic preparedness and ensure rapid mobilization of well-coordinated and independent advice in future emergencies. This review also identified pressing areas for further inquiry to strengthen science advice for public health in Canada, including to assess the independence of science advisory actors and the interaction between federal and subnational authorities.

1 June 2021 in Preventive Medicine
Verified
Journal Article
Closed access
DBDominika Bhatia
Dominika Bhatia
RSRinku Sutradhar
Rinku Sutradhar
JTJill Tinmouth
Jill Tinmouth
SSSimron Singh
Simron Singh
CLCindy Lau
Cindy Lau
LLLorraine L. Lipscombe
Lorraine L. Lipscombe

20 November 2021 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
DBDominika Bhatia
Dominika Bhatia
RSRinku Sutradhar
Rinku Sutradhar
PAPeter C. Austin
Peter C. Austin
VGVasily Giannakeas
Vasily Giannakeas
LJLiisa Jaakkimainen
Liisa Jaakkimainen
LLLorraine L. Lipscombe
Lorraine L. Lipscombe

23 March 2022 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
DBDominika Bhatia
Dominika Bhatia
RSRinku Sutradhar
Rinku Sutradhar
LPLawrence F. Paszat
Lawrence F. Paszat
LRLinda Rabeneck
Linda Rabeneck
SSSimron Singh
Simron Singh
LLLorraine L. Lipscombe
Lorraine L. Lipscombe
INTRODUCTION: Fecal occult blood tests (FOBTs) are colorectal cancer screening tests used to identify individuals requiring further investigation with colonoscopy. Delayed colonoscopy after positive FOBT (FOBT+) is associated with poorer cancer outcomes. We assessed the effect of comorbidity on colonoscopy receipt within 12 months after FOBT+. METHODS: Population-based healthcare databases from Ontario, Canada, were linked to assemble a cohort of 50–74-year-old individuals with FOBT+ results between 2008 and 2017. The associations between comorbidities and colonoscopy receipt within 12 months after FOBT+ were examined using multivariable cause-specific hazard regression models. RESULTS: Of 168,701 individuals with FOBT+, 80.5% received colonoscopy within 12 months. In multivariable models, renal failure (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.62–0.82), heart failure (HR 0.77, CI 0.75–0.80), and serious mental illness (HR 0.88, CI 0.85–0.92) were associated with the lowest colonoscopy rates, compared with not having each condition. The number of medical conditions was inversely associated with colonoscopy uptake (≥4 vs 0: HR 0.64, CI 0.58–0.69; 3 vs 0: HR 0.75, CI 0.72–0.78; and 2 vs 0: HR 0.87, CI 0.85–0.89). Having both medical and mental health conditions was associated with a lower colonoscopy uptake relative to no comorbidity (HR 0.88, CI 0.87–0.90). DISCUSSION: Persons with medical and mental health conditions had lower colonoscopy rates after FOBT+ than those without these conditions. Better strategies are needed to optimize colorectal cancer screening and follow-up in individuals with comorbidities.